These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 18329537)

  • 21. A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis.
    Bibi Y; Gottlieb AB
    J Am Acad Dermatol; 2008 Oct; 59(4):654-8. PubMed ID: 18571768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategy for treatment of fibrosis in systemic sclerosis: Present and future.
    Yanaba K
    J Dermatol; 2016 Jan; 43(1):46-55. PubMed ID: 26782006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stem cell transplantation: a treatment option for severe systemic sclerosis?
    van Laar JM; Farge D; Tyndall A
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii35-8. PubMed ID: 19022811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted anticytokine therapy and the failing heart.
    Mann DL
    Am J Cardiol; 2005 Jun; 95(11A):9C-16C; discussion 38C-40C. PubMed ID: 15925559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Interstitial pulmonary disease in systemic scleroderma: treatment].
    Hellmich B; Schnabel A; Bauer T; Schatz H
    Dtsch Med Wochenschr; 2002 Mar; 127(10):520-2. PubMed ID: 11884997
    [No Abstract]   [Full Text] [Related]  

  • 26. Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis.
    Hemmatazad H; Rodrigues HM; Maurer B; Brentano F; Pileckyte M; Distler JH; Gay RE; Michel BA; Gay S; Huber LC; Distler O; Jüngel A
    Arthritis Rheum; 2009 May; 60(5):1519-29. PubMed ID: 19404935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pirfenidone.
    Lasky J
    IDrugs; 2004 Feb; 7(2):166-72. PubMed ID: 15057662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Systemic sclerosis].
    Tamborrini G; Distler M; Distler O
    Med Monatsschr Pharm; 2008 May; 31(5):162-70; quiz 171-2. PubMed ID: 18552072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular therapy of systemic lupus erythematosus.
    Tyndall A
    Lupus; 2009 Apr; 18(5):387-93. PubMed ID: 19318389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunosuppression followed by autologous hematopoietic stem cell transplantation for the treatment of severe systemic lupus erythematosus, systemic sclerosis and rheumatoid arthritis].
    Giebel S; Zoń-Giebel A; Błach A; Kucharz EJ; Hołowiecki J
    Pol Arch Med Wewn; 2003 Aug; 110(2):891-7. PubMed ID: 14682229
    [No Abstract]   [Full Text] [Related]  

  • 31. Systemic sclerosis and localized scleroderma in childhood.
    Zulian F
    Rheum Dis Clin North Am; 2008 Feb; 34(1):239-55; ix. PubMed ID: 18329543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adult stem cell transplantation in autoimmune disease.
    Tyndall A; Gratwohl A
    Curr Opin Hematol; 2009 Jul; 16(4):285-91. PubMed ID: 19465851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Scleroderma therapy: clinical overview of current trends and future perspective.
    Topal AA; Dhurat RS
    Rheumatol Int; 2013 Jan; 33(1):1-18. PubMed ID: 23011088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hematopoietic stem cell transplantation in autoimmune diseases].
    Albarracín F; López Meiller MJ; Naswetter G; Longoni H
    Medicina (B Aires); 2008; 68(2):153-63. PubMed ID: 18499968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Criteria to select molecular targets for anti-fibrotic therapy.
    Distler JH; Distler O
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v12-3. PubMed ID: 18784127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis.
    Badea I; Taylor M; Rosenberg A; Foldvari M
    Rheumatology (Oxford); 2009 Mar; 48(3):213-21. PubMed ID: 19022832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current approaches to the management of early active diffuse scleroderma skin disease.
    Nihtyanova SI; Denton CP
    Rheum Dis Clin North Am; 2008 Feb; 34(1):161-79; viii. PubMed ID: 18329538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study.
    Levy Y; Amital H; Langevitz P; Nacci F; Righi A; Conforti L; Generini S; Matucci Cerinic M; Shoenfeld Y
    Arthritis Rheum; 2004 Mar; 50(3):1005-7. PubMed ID: 15022346
    [No Abstract]   [Full Text] [Related]  

  • 39. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA; Lynch TJ
    Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefit of intravenous immunoglobulin in a patient with longstanding polymyositis/systemic sclerosis overlap syndrome.
    Abelha-Aleixo J; Bernardo A; Costa L
    Acta Reumatol Port; 2015; 40(2):176-8. PubMed ID: 26219970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.